-+ 0.00%
-+ 0.00%
-+ 0.00%

Addex Therapeutics' Neurosterix to Advance Schizophrenia Drug to Phase 2 Trials

MT Newswires·10/08/2026 02:06:25
Listen to the news
02:06 AM EDT, 10/08/2026 (MT Newswires) -- Addex Therapeutics' (ADXN.SW) spin-out company Neurosterix plans to advance its schizophrenia treatment NTX-253 into phase 2 clinical development after completing phase 1 studies. The biopharmaceutical company said Thursday that the study includes single- and multiple-ascending-dose components and incorporates food-effect and cerebrospinal fluid assessments. The studies enrolled both healthy volunteers and patients with stable schizophrenia.